BPI-9016M is a novel small-molecule TKI targeting both c-MET and AXL developed by Betta Pharmaceuticals Co., Ltd, Hangzhou, China., which can suppress tumor cell growth, migration and invasion of lung adenocarcinoma [19]. This evidence concerns the gene MET and neoplasm.